Abstract. Endoscopic thermal therapy and formalin are being increasingly recommended for the treatment of chronic hemorrhagic radiation proctitis. It may be too early, however, to discard pharmacologic agents from the management process, especially in medical institutions where specialized equipment is unavailable. We prospectively assessed the effectiveness of medical therapy in 14 consecutive patients with chronic hemorrhagic radiation proctitis from July 1999 to June 2001. All 14 subjects were women (mean age 56 years), 13 of whom had had radiotherapy for cancer of the cervix. The median time to onset of symptoms following irradiation was 16 months. Six patients had a hemoglobin level of < 8 g/dl, and blood transfusion was required in 11 patients. In five patients (36%) initially treated with hydrocortisone enemas prior to referral, this treatment continued; and the remaining nine patients were commenced on sucralfate enemas. Two patients given rectal hydrocortisone continued to bleed and were treated with sucralfate enemas and topical formalin, respectively. Rectal sucralfate suspension effectively procured symptomatic alleviation in all 11 patients. Rectal bleeding recurred in two patients who had been managed exclusively with hydrocortisone and sucralfate enemas, respectively, over a mean follow-up of 6 months. Both patients were managed with topical formalin, which controlled their symptoms. Even though the number of subjects in this study is small, sucralfate enema can be recommended as an effective first-line agent for managing patients with chronic hemorrhagic radiation proctitis. The use of more specialized therapy can therefore be reserved for cases where primary treatment failure occurs with sucraifate therapy.
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The incidence of chronic radiation proctitis is largely unknown, which is directly related to the lack of prospective studies. Radiation proctitis may be chronic or recurrent, and the changes due to radiation exposure range from mild to severe, the latter accounting for 2% to 5% of cases [1, 2] . Complications related to radiation proctitis are troublesome, with rectal bleeding being the most common symptom. At the severe end of the spectrum, massive blood transfusion may be required for even life-threatening blood loss in rare circumstances.
There has been a gradual decline in the incidence of radiation proctitis, which is largely attributed to improved modes of radiation delivery. The overall management of chronic radiation proctitis has been unsatisfactory, as only a few treatment options of Correspondence to: Y.A. Gul, M.B., B.Ch., Department of General Surgery, Universi .ty Putra Malaysia, 8th Floor, Grand Seasons Avenue, 72 Jln Pahang, 53000 Kuala Lumpur, Malaysia, e-mail: yunus@medic. upm.edu.my varying efficacy are available. It is often difficult to predict if patients will respond to a particular form of therapy, and treatment strategies contint,c to be poorly defined. Nonsurgical management, however, is preferable to surgical treatment, as the latter is associated with hight,, morbidity in view of the presence of irradiated tissues having a predilection for poor healing.
Endoscopic interventions, which are rapidly gaining acceptance as an effective form of l,'eatment [3] , require expertise and specialized equipment, which is often expensive and not widely available, especially in medical institutions of developing countries. Furthermore, endoscopic therapy and rectal topical formalin are associated with complicqtitms [3] that can be potentially reduced by avoiding the use of such measures as first-line agents. Rectal sucralfate suspension, which is largely devoid of side effects and which has been previously shown to be effective for managing rectal bleeding secondary to radiation-induced proctosigmoiditis [4, 5] , may therefore Ctmlinue to play a meaningful role in the management of this condition. It is imperative that effective therapy for radiation-induced proctitis is identified and utilized accordingly, and that agcJlls of doubtful or no benefit are abandoned in an attempt I~ reduce unnecessary morbidity.
We prospectively cvaltutled patients with chronic hemorrhagic radiation proctitis wire wcrc being managed with topical pharmacologic agents on initial clinical presentation to assess the effectiveness of this mode of Ircatment.
Patients and Methods
Patients with chronic hem~n'rhagic radiation proctitis who were referred to our surgical unil for further management were prospectively followed up ~wer a period of 2 years (July 1999 to June 2001). Symptoms indicative of chronic hemorrhagic radiation proctitis were assessed and correlated with endoscopic and histologic findings. Rectal bleeding was a prerequisite for inclusion in the study. Rectal blecdin!, was graded as severe (> 10 episodes of bleeding a week), mild (5-9 episodes of bleeding a week), or minimal (< 5 episodes ~1' bleeding a week). Endoscopic findings were graded according I,, fhe presence of erythema, granularity,, telangiectasia, and ulceralion. Patients with negative histology indicative of radiation-induced damage were managed as having chronic radiation proctitis based on the clinical presentation and endoscopic findings. Patients with concomitant radiation-induced rectovaginal fistulas were managed primarily with formalin and were excluded from medical therapy owing to their inability to retain enema preparations. Steroid enemas, which were hydrocortisone-based, and sucralfate enemas (2 g in 20 ml of water) were administered twice daily for 2 to 6 weeks. Rectal formalin (4%) was applied in resistant cases where there was a poor response to sucralfate or hydrocortisone enemas. Formalin was applied directly to the rectal mucosa by cotton wool dabbing, with the patient under sedation and in the lithotomy position. Treatment failure was defined as no improvement in the severity of bleeding up to 1 week following commencement of treatment.
Results
A total of 16 consecutive patients (all women) presented with symptoms of rectal bleeding and suspected chronic radiation proctiffs over the 2-year study period. Two patients had concurrent rectovaginal fistulas (one recurrent cancer of the cervix and one radiation-induced) and were excluded from the study. Carcinoma of the cervix accounted for 13 of the women, 3 of whom had had intracavitary irradiation. The remaining patient had had radiotherapy for endometrial cancer. The mean radiation dose was 5400 cGy.
Symptoms of bleeding per rectum occurred at a median of 16 months (range 14-34 months) following radiation treatment. Associated symptoms included pain (three patients), diarrhea (two patients), passage of mucus (four patients), and hematuria (one patient). Bleeding was graded as severe in six patients, moderate in six patients, and minimal in two patients (Table 1) . Blood transfusion was required in 11 patients, the mean transfusions required being 3 units. All 14 patients underwent flexible sigmoidoscopy (6 patients) or colonoscopy (8 patients) to confirm the findings, complemented by rectal biopsies and histologic analysis. Five patients who were initially treated with hydrocortisone enemas for a mean of 3 days prior to referral had this treatment continued. The remaining nine patients were administered sucralfate enemas (20 g in 20 ml of water) administered twice daily for 2-6 weeks.
Endoscopic findings confirmed inflammatory changes consistent with radiation proctitis in all 14 patients (Table 1) . The most common finding was telangiectasia (seven patients) and granularity of the mucosa (five patients). Two patients had associated features of mucosal inflammation in the lower sigmoid colon as well. Two patients administered hydrocortisone enemas continued bleeding 5 days after admission to our unit, and further treatment with sucralfate enemas (one patient) or formalin application (one patient) were instituted. They proved successful in arresting the hemorrhage. The mean duration of hospitalization was 13 days (range 6-26 days).
Over a mean follow-up of 6 months, two patients who were managed exclusively with rectal topical hydrocortisone and sucralfate, respectively, experienced recurrent rectal bleeding associated with a fall in the hemoglobin level to less than 10 g/dE Both patients were managed with topical formalin dabbing, which provided symptomatic relief. Follow-up endoscopy was performed in 12 patients. The most common finding was pale rectal mucosa with minor telangiectatic spots, which was evident in seven patients. Notably, worsening or progression of disease, including stricture formation, has not been encountered in any of the patients.
Discussion
Most of the patients who suffer from radiation proctitis are those who have had pelvic malignancies that benefit from radiation therapy, especially cervical cancer in women and prostatic cancer in men. The development of side effects related to radiation therapy depends on the amount and exposure of normal tissues to radiation [6] . Doses exceeding 5000 cGy increase the potential of radiation damage, and the incidence could be as high as 30% when the radiation dose exceeds 7000 cGy [7] . In addition to external beam therapy, intracavitary radiation delivery has been shown to increase the risk of developing chronic radiation proctitis [8] . Steroid enemas or 5-aminosalicyiic acid-based compounds have an established role in the management of ulcerative proctitis or inflammatory bowel disease. The efficacy of these agents in the management of chronic radiation proctitis has yet to be proven even though Kochhar et al. [4] demonstrated slight symptomatic alleviation in patients treated with steroid enemas and oral sulfasalazine in their small prospective double-blind study. The continued utilization of steroids is probably related to the ready availability of this agent, especially in the form of enema preparations. Lack of clear guidelines pertaining to the management of radiation proctitis could also be responsible for this practice as demonstrated by the commencement of steroid enemas in 36% of patients prior to referral in our series. We altered the management only when no or a poor response was noted in relation to symptoms of bleeding per rectum. There were three (60%) treatment-related failures with steroid therapy in our series (two early and one late).
Sucralfate, which is a basic aluminum salt of sucrose octasulfate and used in the treatment of peptic ulceration, has shown promise in the management of chronic radiation proctitis. It forms an adherent complex binding to the damaged mucosa, rendering it a local cytoprotective agent. It probably acts at the mucosal level by promoting angiogenesis and reducing epithelium-related micro-vascular injury [9] . A prospective double-blind randomized study comparing sucralfate with rectal steroids plus oral sulfasalazine for chronic radiation proctitis by Kochhar et al. confirmed this, even though the follow-up period was short [4] . The long-term efficacy of sucralfate enemas in patients with chronic hemorrhagic radiation proctitis was confirmed in a prospective analysis of 26 patients, 17 (71%) of whom had no further bleeding during a median follow-up of 45 months [5] . Seven patients who had recurrent bleeding responded to reestablishment of the treatment. As with other forms of medical therapy, there have been no other large prospective studies to support these findings. Apart from having the advantage of being relatively easy to administer, rectal sucralfate also has the advantage of not having any adverse effects. Even though our cohort of patients is small, we found sucralfate to be efficacious in 10 of 11 patients who were commenced on this therapy. Recurrent rectal bleeding was encountered on follow-up in a single case, and it was managed with rectal formalin primarily because of the patient's refusal to undergo prolonged treatment in hospital and the inability to administer the topical sucralfate preparation at home. The duration required for sucralfate treatment could be considered a drawback, as treatment may be required for up to 4 weeks to obtain satisfactory results. We usually discharge patients upon cessation of rectal bleeding when it is possible for the patient to have the treatment continued at home.
Local application of the diseased rectal mucosa with formalin has shown promise in the treatment of hemorrhagic radiation proctitis [3] . Formalin causes chemical cauterization of the inflamed or fragile telangiectatic rectal mucosa in radiation proctitis. The treatment is inexpensive, easy to perform, and does not appear to have a high complication rate. The stimulus for this treatment was initiated by successful reports of treatment of hemorrhagic radiation cystitis with 10% intravesical formaldehyde [10] . Direct contact of formalin with the involved rectal mucosa for a few minutes is necessary to achieve the required effect, which usually takes the form of mucosal blanching [11] . Formalin may be applied to the rectal mucosa by direct application of a gauze impregnated with formalin or by instillation techniques. Direct application of formalin under visualization is better than blind irrigation, as it avoids unnecessary complications and contact of formalin with normal rectal mucosa. Mathai and Seow-Choen [12] employed gauze impregnated with 4% formalin that was locally applied by direct visualization of the rectal mucosa in 29 patients with hemorrhagic radiation proctitis, 15 of whom had not responded to medical treatment, including local steroid application. At a median follow-up of 1 year, 22 patients (76%) had no further bleeding. Only a single complication in the form of a rectal stricture was reported. Other complications that have been reported with formalin include minor liquid stool incontinence and rectal ulceration [13] . We have been reluctant to use formalin as first-line treatment for patients with chronic hemorrhagic radiation proctitis in view of the reported side effects.
Electrocoagulation thermal therapy has been used successfully for chronic hemorrhagic radiation proctitis and is beginning to emerge as an effective treatment [3, 14] . Two or three sessions are usually required before the hemorrhagic symptoms are completely controlled. Like pharmacologic agents, repeated treatment can be employed in patients who experience recurrent bleeding episodes. The high cost and specialized equipment required with these techniques is a disadvantage that is not encountered with the other available treatment options. Perforation of the diseased rectum is another potential hazard that must be considered when employing these methods. The argon laser is safer than the Nd: Yag laser in this respect, with the added advantage of causing less transmural damage and hence avoiding the development of rectal strictures [15, 16] .
Surgical intervention for chronic radiation proctitis is usually reserved for patients who have intractable symptoms that have failed to respond to medical therapy and patients with radiationinduced fistula formation. Resection of the diseased rectum may be necessary, which is a hazardous procedure that necessitates dissection in an irradiated field with potential complications that range from bleeding to anastomotic leaks and sepsis. Surrounding pelvic organs, including the ureter, is also at risk during the procedure. Proctectomy and a Hartmann's procedure, abdominoperineal resection, and coloanal anastomosis are all surgical options with inherent advantages and disadvantages. It must be stressed that they are major procedures that should be performed in specialist units that undertake similar approaches on a regular basis for other colorectal pathologies, such as rectal cancer.
The overall management of radiation proctitis is gradually improving, though guidelines on the ideal form of management options that are available continue to be ill-defined. Interventional agents in the form of argon plasma coagulation and local formalin application have shown promise [3] even though their long-term effectiveness has yet to be confirmed. Despite the possibility of requiring prolonged treatment, pharmacologic agents such as sucralfate still appear to play a role, especially in cases of mild radiation proctitis or in institutions where sophisticated equipment and the expertise for thermal energy application are not available. The lack of reported complications associated with sucralfate therapy and the ease of application render it an attractive first-line agent. Treatment failure can be managed by formalin dabs, which apart from being economical are relatively easy to apply.
Management of chronic hemorrhagic radiation proctitis should be tailored to suit the facilities available in an institution. Establishing a treatment protocol is important, as the condition may be managed in the early stages by a number of medical specialists, including surgeons, gynecologists, gastroenterologists, or even oncologists. Having a routine protocol would help avoid treatmentrelated delays and unnecessary morbidity. Failure of medical treatment and formalin application should prompt the physician to refer the patient to a center with available resources for dealing with complicated cases. Additional randomized prospective studies will be helpful for confirming the long-term efficacy of current available treatment options in the management of chronic hemorrhagic radiation proctitis. patientes. Chez les cinq patientes (36%) qui avaient 6t6 trait~s initialement par des lavements A I'hydrocortisone avant d'etre adress~s chez nous, ce traitement est rest~ sans changement: les neuf autres patients ont eu des lavements au sucralfate. Deux patients ont continu6 de saigner malgr~ les lavements h I'hydrocortisone et ont ~t~ ensuite trait~s par des lavements au sucraifate. La suspension au sucralfate a ~t~ efficace chez 11 patientes en ce qui concerne ram~lioration symptomatique. On a constat~ une r6cidive d'h~morragie chez deux patientes trait6es initialement exclusivement par les lavements ~ rhydrocortisone et sucraifate sur un suivi moyen de 6 mois. Toutes deux ont ~t~ trait~es par des lavements locaux au formol, ce qui a contr61~ les sympt6mes. Bien que ie nombre de sujets soit petit, les lavements au sucralfate peuvent ~tre recommand~s en premiere ligne pour le traitement de proctite radique chronique h6morragique. L'utilisation de traitements plus sp6cifiques est r~serv6e aux patients pour qui ie traitement par des lavements au sucralfate a 6chou6.
Resumen. En el tratamiento de ia hemorragia cr6nica por una proctitis secundaria a irradiaci6n, se recomienda cada vez mds la terapia t~rmica endosc6pica y el tratamiento con formalina. Sin embargo, parece que todavfa es pronto para descartar los agentes farmacol6gicos hasta ahora empleados, especialmente en centros m~dicos que carecen del equipamiento necesario para aplicar esta nueva terapia. Evaluamos prospectivamente la eficacia del tratamiento m~dico en 14 pacientes con radioproctitis con hemorragia cr6nica, atendidos entre julio de 1999 y junio de 2001. Todos los pacientes eran mujeres (edad media 56 afios), 13 de las cuales fueron sometidas a radioterpia por padecer un c.-incer de cervix. Los sintomas aparecieron a los 16 meses (como promedio) de la irradiaci6n. 6 pacientes presentaban una hemoglobina < 8 g/dl y 11 enfermas requirieron transfusi6n sangufnea. 5 pacientes (36%) al sernos remitidos estaban siendo tratados con enemas de hidrocortisona y este tratamiento se mantuvo, mientras queen los 9 casos restantes se inici6 un tratamiento con enemas de sucralfato. Dos pacientes tratados con hidrocortisona continuaron sangrando y pot ello se indicaron enemas de sucralfato. La suspensi6n rectal de sucralfato fue eficaz en 11 pacientes, mejordndose considerablemente su sintomatologfa. Durante un periodo de seguimiento superior a 6 meses se constataron recidivas de hemorragia rectal en 2 pacientes tratados uno, exclusivamente con hidrocortisona, y otro con sucralfato. En ambos la aplicaci6n t6pica de formalina control6 su sintomatologfa. Aunque la casufstica de este estudio es escasa parece evidente, que el enema de sucralfato debe recomendarse como tratamiento inicial de pacientes con hemorragia crfinica por proctitis por irradiaci6n. Otras terapias m.4s especializadas deberfin reservarse para cuando fracase el tratamiento con sucralfato.
